Browse by category

MyPhenome test predicts GLP-1 response and obesity risk in large, diverse populations

Phenomix Sciences has announced results from new research, presented at Obesity Week 2025, demonstrating the continued clinical utility of its MyPhenome test, backed by a proprietary machine-learning Genetic Risk Score (GRS), in predicting obesity and treatment outcomes across large and diverse patient populations. The studies, led by Mayo Clinic researcher and Phenomix co-founder Dr Andres Acosta, further validate the MyPhenome test's ability to predict patient response to G

OMMs appear to be valid alternatives to EBP and MBS for mild-to-moderate obesity, but surgery more effective for patients with a higher degree of obesity

39 minutes ago

MyPhenome test predicts GLP-1 response and obesity risk in large, diverse populations

2 hours ago

Apnimed’s sulthiame's demonstrates efficacy in obstructive sleep apnoea

1 day ago

Browse by category

MyPhenome test predicts GLP-1 response and obesity risk in large, diverse populations

Browse by tag

OMMs appear to be valid alternatives to EBP and MBS for mild-to-moderate obesity, but surgery more effective for patients with a higher degree of obesity

MyPhenome test predicts GLP-1 response and obesity risk in large, diverse populations

Apnimed’s sulthiame's demonstrates efficacy in obstructive sleep apnoea

Back to Top